These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 8133086

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
    St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, Larder BA.
    Science; 1991 Sep 27; 253(5027):1557-9. PubMed ID: 1716788
    [Abstract] [Full Text] [Related]

  • 23. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
    Nielsen C, Bruun L, Mathiesen LR, Pedersen C, Gerstoft J.
    AIDS; 1996 Jun 27; 10(6):625-33. PubMed ID: 8780817
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.
    Venturi G, Romano L, Catucci M, Riccio ML, De Milito A, Gonnelli A, Rubino M, Valensin PE, Zazzi M.
    Eur J Clin Microbiol Infect Dis; 1999 Apr 27; 18(4):274-82. PubMed ID: 10385016
    [Abstract] [Full Text] [Related]

  • 26. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.
    Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC.
    Ann Intern Med; 1994 Aug 15; 121(4):263-8. PubMed ID: 7518658
    [Abstract] [Full Text] [Related]

  • 27. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
    Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Aguiniga E, Halpern J, Merigan TC.
    J Acquir Immune Defic Syndr (1988); 1994 Aug 15; 7(8):832-8. PubMed ID: 7517448
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P.
    J Med Virol; 1999 Dec 15; 59(4):507-11. PubMed ID: 10534734
    [Abstract] [Full Text] [Related]

  • 34. High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy.
    Husson RN, Shirasaka T, Butler KM, Pizzo PA, Mitsuya H.
    J Pediatr; 1993 Jul 15; 123(1):9-16. PubMed ID: 8391570
    [Abstract] [Full Text] [Related]

  • 35. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction.
    Richman DD, Guatelli JC, Grimes J, Tsiatis A, Gingeras T.
    J Infect Dis; 1991 Dec 15; 164(6):1075-81. PubMed ID: 1720152
    [Abstract] [Full Text] [Related]

  • 36. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.
    Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC.
    Antimicrob Agents Chemother; 1997 Apr 15; 41(4):757-62. PubMed ID: 9087484
    [Abstract] [Full Text] [Related]

  • 37. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
    Schooley RT, Ramirez-Ronda C, Lange JM, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder BA, St Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR, Kinghorn I, Steel H, Rooney JF.
    J Infect Dis; 1996 Jun 15; 173(6):1354-66. PubMed ID: 8648207
    [Abstract] [Full Text] [Related]

  • 38. Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.
    Pellegrin I, Segondy M, Garrigue I, Izopet J, Montes B, Pellegrin JL, Reynes J, Massip P, Puel J, Fleury H.
    J Acquir Immune Defic Syndr; 2000 Dec 15; 25(5):465-6. PubMed ID: 11141248
    [No Abstract] [Full Text] [Related]

  • 39. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
    Picard V, Angelini E, Maillard A, Race E, Clavel F, Chêne G, Ferchal F, Molina JM.
    J Infect Dis; 2001 Sep 15; 184(6):781-4. PubMed ID: 11517441
    [Abstract] [Full Text] [Related]

  • 40. Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients.
    Calderón EJ, Torres Y, Medrano FJ, Luque F, Larder B, Rey C, Sánchez-Quijano A, Lissen E, Leal M.
    Eur J Clin Microbiol Infect Dis; 1995 Jun 15; 14(6):512-9. PubMed ID: 7588824
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.